B
BioConsortia
Agricultural biotechnology company that uses a proprietary method for the selection of
About BioConsortia
BioConsortia, Inc. operates as a research and development company at the forefront of agricultural biotechnology, focusing on microbial solutions to enhance crop yields and promote sustainability. Established in 2014, the company is the parent of BioDiscovery New Zealand, a firm founded in 1994 that developed the foundational technology. The decision to globalize under the BioConsortia name involved relocating headquarters to Davis, California, to better access U.S. markets and research opportunities.
Read full description
The company was significantly shaped by CEO Marcus Meadows-Smith. After a successful career in the agrichemical and biopesticide industry, including leading AgraQuest until its acquisition by Bayer CropScience for nearly $500 million, Meadows-Smith was drawn out of a brief retirement by the potential he saw in BioDiscovery's technology. He joined as CEO on the condition the company move to Davis, California, bringing his extensive experience in commercializing biological products for agriculture. The executive team includes other veterans from AgraQuest and Bayer CropScience, such as Christina Huben (SVP, Operations & Administration) and Dr. Hong Zhu (SVP, Research & Development), who collectively contribute decades of experience in the biologics sector.
BioConsortia's business model centers on developing advanced microbial products through to registration and then partnering with larger agricultural companies for commercialization and distribution. Revenue is generated through these strategic partnerships, which have included a major collaboration with The Mosaic Company to develop and launch nitrogen-fixing microbial products. This R&D-focused approach allows the company to concentrate on its core competency: discovery. The firm serves farmers globally across a wide array of crops, including corn, wheat, fruits, and vegetables, by providing solutions through its partners.
The core of BioConsortia's technical advantage lies in its patented Advanced Microbial Selection (AMS) process, a directed selection platform that rapidly identifies beneficial microbes. This system, combined with the GenePro genomics and gene-editing platform, allows scientists to discover and design microbes that enhance nitrogen fixation, control pests and diseases, and improve overall plant health. The product pipeline includes nitrogen-fixing microbes that reduce the need for synthetic fertilizers, biostimulants for yield enhancement, and biopesticides like fungicides and nematicides. A key feature of their products is the use of robust, spore-forming bacteria, enabling a shelf-life of over two years and on-seed viability for more than 18 months, which simplifies adoption for growers.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Davis, United States
- Employees
- 50
- Open positions
- None listed
- Dealroom signal
- 39.0/100
- Sub-industry
- AgriTech
- Sector
- Food, Biotechnology, Crop Protection, Biopesticides, Synthetic Biology, Sustainable Development Goals, Biotech and Pharma, Regenerative Agriculture, Climate Tech, Hard Tech, DT and LS, science-based, nt
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Aug 2025 | $15M | $60M | Otter Capital | ↗ |
| LATE VCOther financing | Apr 2024 | $15M | $60M | Otter Capital | ↗ |
Growth signals
Latest recorded traffic for BioConsortia is 1.5K monthly website visits, up 7.1% over the last three months. BioConsortia's team declined 2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Khosla Ventures- OCOtter Capital
Series B and later2 investors entered at this stage
Square 1 Bank
Outset Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioConsortia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioConsortia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







